Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12993708 | 0.90 | EPHX2 (0.54) | EPHX2LSS | |
| SCHEMBL7848048 | 0.87 | EPHX2 (0.63) | EPHX2L3MBTL1NR1H4CA1CA2 | |
| SCHEMBL22915155 | 0.83 | HSP90AA1 (0.49) | EPHX2HPGDS | |
| SCHEMBL30643074 | 0.83 | HSP90AA1 (0.49) | EPHX2HPGDS | |
| SCHEMBL20810002 | 0.82 | POLB (0.45) | EPHX2L3MBTL1HPGDS | |
| SCHEMBL17092299 | 0.82 | ITK (0.46) | EPHX2LSSRORCHPGDS | |
| SCHEMBL8376682 | 0.81 | KDM4E (0.57) | MLLT1L3MBTL1HPGDS | |
| SCHEMBL2138280 | 0.81 | EPHX2 (0.61) | EPHX2L3MBTL1NR1H4CA1CA2 | |
| SCHEMBL14538195 | 0.80 | NAMPT (0.48) | EPHX2LSSRORCNR1H4SCN3A | |
| SCHEMBL14497665 | 0.79 | EPHX2 (0.56) | EPHX2LSSNR1H4SCN3ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | EPHX2 2199/4885LSS 1178/4885MLLT1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.